CONCORD, MA / ACCESSWIRE / May 6, 2024 / Xeris Biopharma Holdings, Inc. (Nasdaq:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has entered into an exclusive worldwide collaboration and license agreement with Beta Bionics, Inc. for the development and commercialization of a glucagon product utilizing Xeris' XeriSol™ technology for use in Beta Bionics' proprietary bi-hormonal pump and pump systems.
Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics
Beta Bionics Announces iLet Bionic Pancreas Is Now Added to the Express Scripts
CONCORD, MA / ACCESSWIRE / August 30, 2023 / Beta Bionics, Inc., a pioneering leader in the development of advanced diabetes management solutions, is thrilled to announce the successful closure of its Series D funding round securing $100 million in new equity capital.
CONCORD, MA / ACCESSWIRE / June 22, 2023 / Beta Bionics, Inc. - a medical technology company focused on diabetes - announces FDA 510(k) clearance for compatibility with the Fiasp® Pumpcart® (insulin aspart) prefilled insulin cartridge. The iLet is the first and only automated insulin-delivery system that does not require carb counting, fully automates 100% of all user insulin doses, and will provide users the choice of three insulins - Novolog®, Humalog® and Fiasp® Pumpcart®.
Artificial pancreas systems synchronize an insulin pump and continuous glucose monitor with the goal of delivering an almost completely hands-off approach to diabetes management—and the newest one cleared by the FDA aims to make that goal even easier to achieve.
CONCORD, MA / ACCESSWIRE / May 22, 2023 / Beta Bionics, Inc. - a medical technology company focused on diabetes - announces FDA 510(k) clearance and the commercial launch of the iLet Bionic Pancreas. The iLet is the first and only automated insulin-delivery system that does not require carb counting and fully automates 100% of all user insulin doses - which means no calculations, less input, and less burden for the user. The iLet is paired with the Dexcom G6 Continuous Glucose Monitoring System.
CONCORD, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. — a clinical-stage medical technology company — announced the appointment of Steven Russell, MD, Ph.D., to the role of Chief...
CONCORD, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. — a clinical-stage medical technology company committed to the design, development, and commercialization of the iLet® Bionic Pancreas System — today announced the appointment of Sean Saint to the role of Chief Executive Officer. Mr. Saint will also serve on the Beta Bionics Board of Directors. Martha Goldberg Aronson, who has served as interim CEO since February, will work with Mr. Saint through a transition period and will remain on the Beta Bionics Board of Directors.